DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia - PubMed (original) (raw)
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
K H Metzeler et al. Leukemia. 2012 May.
No abstract available
Conflict of interest statement
Conflict of interest
The authors declare no conflict of interest.
Figures
Figure 1
Complete remission rate according to DNMT3A mutational status in AML patients treated with decitabine.
References
- Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25:1908–1915. - PubMed
- Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837–841. - PubMed
- Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–2054. - PubMed
- Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429–2440. - PubMed
- Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794–1803. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical